Monday, January 18, 2021

admin

931 POSTS2 COMMENTS

GSK presents positive efficacy data of dostarlimab at ASCO Gastrointestinal Cancers Symposium

January 16, 2021: "GlaxoSmithKline (GSK) plc announced updated data from GARNET cohort F evaluating dostarlimab in mismatch repair-deficient (dMMR) non-endometrial advanced solid...

Bharat Biotech signs agreement with Precisa Medicamentos for supply of ‘COVAXIN™’ to Brazil

January 12, 2020: "Bharat Biotech announced that it has signed an agreement with Precisa Medicamentos for the supplies of COVAXIN™ to Brazil.

What Is a Blockbuster Drug?

What Is a Blockbuster Drug? "Blockbuster drugs are those that generate at least $1 billion of revenue per...

Boehringer Ingelheim and Enara Bio join forces to discover Cancer Immunotherapies

January 12th, 2021: Boehringer Ingelheim and Enara Bio announced that they have entered into a strategic collaboration and licensing agreement to research...

Novartis ligelizumab receives FDA Breakthrough Therapy designation for CSU

Jan 14, 2021: "Novartis announced that the U.S. Food and Drug Administration (FDA) has granted ligelizumab (QGE031) Breakthrough Therapy designation for the...

ViiV Healthcare receives EU Marketing Authorisation for the dolutegravir for HIV

ViiV Healthcare receives EU Marketing Authorisation for the first-ever dispersible-tablet formulation of dolutegravir, Tivicay, a treatment for children living with HIV in...

Roche’s Tecentriq/Avastin combination improves survival in liver cancer

January 12, 2021: Roche will present updated overall survival (OS) data from the Phase III IMbrave150 study evaluating Tecentriq® (atezolizumab) in combination...

Vir Biotechnology and GSK announce NHS-supported AGILE study for COVID-19

January 12, 2021: Vir Biotechnology and GlaxoSmithKline announced an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild...

Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene

January 11, 2021: "Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene, Ltd. in major markets outside of China,...

FDA Releases Artificial Intelligence/Machine Learning Action Plan

January 12, 2021: "The U.S. Food and Drug Administration released the agency’s first Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD)...

FDA Conditionally Approves First Oral Tablet to Treat Lymphoma in Dogs

January 11, 2021: "The U.S. Food and Drug Administration conditionally approved Laverdia-CA1 (verdinexor tablets) to treat dogs with lymphoma, a type of...

Promising new treatment strategy for men with drug-resistant prostate cancer

January 12, 2020: "A new experimental drug could offer a promising approach to treating men with advanced prostate cancer which does not...

TOP AUTHORS

931 POSTS2 COMMENTS

Most Read

GSK presents positive efficacy data of dostarlimab at ASCO Gastrointestinal Cancers Symposium

January 16, 2021: "GlaxoSmithKline (GSK) plc announced updated data from GARNET cohort F evaluating dostarlimab in mismatch repair-deficient (dMMR) non-endometrial advanced solid...

Bharat Biotech signs agreement with Precisa Medicamentos for supply of ‘COVAXIN™’ to Brazil

January 12, 2020: "Bharat Biotech announced that it has signed an agreement with Precisa Medicamentos for the supplies of COVAXIN™ to Brazil.

What Is a Blockbuster Drug?

What Is a Blockbuster Drug? "Blockbuster drugs are those that generate at least $1 billion of revenue per...

Boehringer Ingelheim and Enara Bio join forces to discover Cancer Immunotherapies

January 12th, 2021: Boehringer Ingelheim and Enara Bio announced that they have entered into a strategic collaboration and licensing agreement to research...